## Objective: To determine whether interferon-alpha (ifnalpha) reduces the severity of skin involvement in early (<3 years) diffuse scleroderma. ## Methods: In a randomized, placebo-controlled, double-blind trial, 35 patients with early scleroderma received subcutaneous injections of either ifnal
β¦ LIBER β¦
Comprehensive chromosome screening (CCS) with vitrification results in improved clinical outcome in women >35 years: a randomized control trial
β Scribed by W.B. Schoolcraft; E. Surrey; D. Minjarez; R.L. Gustofson; R.T. Scott Jr.; M.G. Katz-Jaffe
- Book ID
- 116480578
- Publisher
- Elsevier Science
- Year
- 2012
- Tongue
- English
- Weight
- 47 KB
- Volume
- 98
- Category
- Article
- ISSN
- 1556-5653
No coin nor oath required. For personal study only.
π SIMILAR VOLUMES
Interferon-Ξ± does not improve outcome at
β
Carol M. Black; Alan J. Silman; Ariane I. Herrick; Christopher P. Denton; Helen
π
Article
π
1999
π
John Wiley and Sons
π
English
β 161 KB
π 1 views
Submerged and transmucosal healing yield
β
Christoph H. F. HΓ€mmerle; Ronald E. Jung; Mariano Sanz; Stephen Chen; William C.
π
Article
π
2011
π
John Wiley and Sons
π
English
β 707 KB
The vitamin D analogue 2MD increases bon
β
Hector F DeLuca; Wendy Bedale; Neil Binkley; J Chris Gallagher; Michael Bolognes
π
Article
π
2011
π
American Society for Bone and Mineral Research
π
English
β 215 KB
π 1 views
## Abstract Most osteoporosis drugs act by inhibiting bone resorption. A need exists for osteoporosis therapies that stimulate new bone formation. 2βMethyleneβ19βnorβ(20__S__)β1Ξ±,25βdihydroxyvitamin D~3~ (2MD) is a vitamin D analogue that potently stimulates bone formation activity in vitro and in
Results of cervical arthroplasty compare
π
Article
π
2011
π
Elsevier Science
π
English
β 42 KB